AVITA Medical CEO and leadership

Mike S. Perry was appointed as Chief Executive Officer (CEO) of AVITA Medical in June 2017, after serving on the Board since February 2013. He brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of over 30 prescription products, 14 of which achieved blockbuster status. Prior to joining AVITA, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014. With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA. Since 2011, has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.

Operations Executive with over twenty five years experience with tissue engineered and cell based medical devices and biologics per ISO 13485, TGA and FDA requirements. Proven leadership, management and organizational skills with high standards for accuracy and execution as demonstrated by career advancement, increased leadership responsibilities and continued realization of department, site and organizational objectives. Excellent relationship, interpersonal and communication skills, including coaching and staff development, motivation, team building and culture development as part of an effective manufacturing operation. Expertise in project management, continuous improvement, budgeting, cost center management, capacity planning, facility management and all phases of cGMP manufacturing operations including; Manufacturing, Quality, Supply Chain, Facilities and Engineering, Process Development, Regulatory, Clinical Operations and CMC team development. Experienced in due diligence activities associated with mergers and acquisitions strategies.

Specialties: Operations, P&L Management, Strategic Planning, Change Leadership, Mergers and Acquisitions, Talent Management, Culture Development, Organizational Planning, Operational Excellence, cGMP Compliance, Regulatory Compliance, Site Management, Due Diligence, Capital Expansion, Lease Negotiation, Infrastructure Assessment

Mike S. Perry was appointed as Chief Executive Officer (CEO) of AVITA Medical in June 2017, after serving on the Board since February 2013. He brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of over 30 prescription products, 14 of which achieved blockbuster status. Prior to joining AVITA, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014. With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA. Since 2011, has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.